GE Healthcare operates the Imanet network of positron emission tomography (PET) imaging sites to provide support from proof-of-concept radiochemistry through to clinical trials. Neuroimage believes tapping into this network will improve the service it can offer clients.
These clients are operating in the challenging and costly area of central nervous system (CNS) treatments. Consequently, information that can help select the most promising candidates for further development is particularly valuable.
“Time, money, and effort will be saved with clinical trials through the collaboration of our two companies, especially in the case of difficult or complex projects”, said Adolfo Cotter, president of contract research organisation (CRO) Neuroimage.
Savings are made by providing clients with an array of information, including delivery to the brain and interaction with the target. Information obtained at this stage can underpin decisions to change administration later in development.
Service offering
Offering PET imaging alongside services from Neuroimage, such as biomarkers and preclinical pathology, allows the companies to offer a more comprehensive range of CNS services.
“Our customers are always looking for ways to link preclinical and clinical data for efficient translational research”, said Eric Agdeppa, imaging solutions manager at GE Healthcare.
The collaboration will allow GE and Neuroimage to provide this link, said Agdeppa, and give clients “a service that integrates the tools they need to remove uncertainty in go/no-go decisions in clinical trials”.